What Biktarvy Treats in HIV
Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is approved for treating HIV-1 infection in adults and children. The FDA lists its primary indications as:
- Complete treatment regimen (no other HIV drugs needed) for treatment-naïve adults.[1]
- Replacement for a current HIV regimen in virologically suppressed adults (HIV RNA <50 copies/mL).[1]
- Treatment for children weighing at least 14 kg who are treatment-naïve or virologically suppressed.[1]
It combines an integrase strand transfer inhibitor (bictegravir) with two nucleoside reverse transcriptase inhibitors.
Who Can Use Biktarvy
Eligible patients include:
- Adults starting HIV treatment for the first time.
- Adults switching from other regimens if their viral load is undetectable.
- Pediatric patients aged 2 years and older (or 6 years with specific weight minimums), either starting treatment or switching if suppressed.[1]
Not approved as initial therapy in patients with known resistance to its components.
How Biktarvy Fits into HIV Guidelines
U.S. DHHS guidelines recommend Biktarvy as a preferred initial regimen for most treatment-naïve adults due to its efficacy, once-daily dosing, and low pill burden. It's also favored for switches in stable patients without resistance.[2]
| Patient Group | Preferred Status |
|---------------|------------------|
| Treatment-naïve adults | Preferred |
| Virologically suppressed adults switching | Preferred |
| Pediatric (≥14 kg) | Preferred option |
Common Off-Label or Investigational Uses
No formal off-label indications exist, but studies explore its role in HBV/HIV coinfection (due to emtricitabine and tenofovir activity against HBV). Not approved as monotherapy or for HBV alone.[1]
Key Warnings and Contraindications
Avoid in patients with prior hypersensitivity or those taking rifampin, St. John's wort, or certain anticonvulsants (e.g., carbamazepine), as they reduce bictegravir levels. Screen for HBV before starting, as discontinuation risks HBV flare.[1]
Lactic acidosis and severe hepatomegaly with steatosis are rare risks with tenofovir-containing regimens.
How It Compares to Other HIV Regimens
Biktarvy outperforms older regimens like dolutegravir/abacavir/lamivudine in switch studies for viral suppression maintenance. Versus Tivicay (dolutegravir) + Descovy, it simplifies to one pill with similar efficacy but better renal/bone safety profile.[2][3]
| Regimen | Pills/Day | Resistance Barrier | HBV Coverage |
|---------|-----------|---------------------|--------------|
| Biktarvy | 1 | High | Yes |
| Triumeq | 1 | High | Partial |
| Dovato | 1 | Moderate | No |
Pediatric Dosing and Considerations
For kids ≥14 kg:
- Tablets for ≥25 kg; dispersible for smaller.
- Adjusted by weight; maintains high barrier to resistance.[1]
When to Avoid or Monitor Closely
Not for creatinine clearance <30 mL/min. Monitor renal function, lipids, and bone density periodically. Pregnancy category use requires weighing benefits vs. risks.[1]
[1]: Biktarvy Prescribing Information (Gilead)
[2]: DHHS HIV Guidelines
[3]: DrugPatentWatch.com - Biktarvy